Điều hòa tự tiêu hoại như một lựa chọn điều trị trong glioblastoma

Witthayanuwat S, Montien P, Supaadirek C et al (2018) Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev 19:2613–2617. https://doi.org/10.22034/APJCP.2018.19.9.2613 Stupp R, Mason W, Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 Thomas A, Tanaka M, Trepel J et al (2017) Temozolomide in the era of precision medicine. Cancer Res 77:823–826. https://doi.org/10.1158/0008-5472.CAN-16-2983 Hegi M, Diserens A, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331 Hottinger A, Stupp R, Homicscko K (2014) Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer 33:32–39. https://doi.org/10.5732/cjc.013.10207 Hunter C, Smith R, Cahill D et al (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66:3987–3991. https://doi.org/10.1158/0008-5472.CAN-06-0127 Singh S, Hawkins C, Clarke I et al (2004) Identification of human brain tumor initiating cells. Nature 432:396–401. https://doi.org/10.1038/nature03128 Patel A, Tirosh I, Trombetta J et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396–1401. https://doi.org/10.1126/science.1254257 Furnari F, Cloughesy T, Cavenee W et al (2015) Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer 15:302–310. https://doi.org/10.1038/nrc3918 Oberoi R, Parrish K, Sio T et al (2016) Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma. Neuro Oncol 18:27–36. https://doi.org/10.1093/neuonc/nov164 Lathia J, Mack S, Mulkearns-Hubert E et al (2015) Cancer stem cells in glioblastoma. Genes Dev 29:1203–1217. https://doi.org/10.1101/gad.261982.115 Ciechomska I (2018) The role of autophagy in neoplastic cells: characteristics of the interdependencies between autophagy and apoptosis; modulation of autophagy as a new therapeutic strategy in the treatment of gliomas. Postep Biochem 64:2. https://doi.org/10.18388/pb.2018_121 Goldhoff P, Clarke J, Smirnov I et al (2012) Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. J Neuropathol Exp Neurol 71:83–89. https://doi.org/10.1097/NEN.0b013e31823fe8f1 Brennan C, Verhaak R, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. https://doi.org/10.1016/j.cell.2013.09.034 Aldape K, Zadeh G, Mansouri S et al (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:829–848. https://doi.org/10.1007/s00401-015-1432-1 Danial N, Hockenbery D (2018) Cell death. In: Hoffman R (ed) Hematology: basic principles and practice, vol 18, 7th edn. Elsevier, Mumbai, pp 186–196 Huang Z, Zhou L, Chen Z et al (2016) Stress management by autophagy: implications for chemoresistance. Int J Cancer 139:23–32. https://doi.org/10.1002/ijc.29990 Yang K, Niu L, Bai Y et al (2019) Glioblastoma: targeting the autophagy in tumorigenesis. Brain Res Bull 153:334–340. https://doi.org/10.1016/j.brainresbull.2019.09.012 Shimizu S, Yoshida T, Tsujioka M et al (2014) Autophagic cell death and cancer. Int J Mol Sci 15:3145–3153. https://doi.org/10.3390/ijms15023145 Kimmelman AC, White E (2017) Autophagy and tumor metabolism. Cell Metab 25:1037–1043. https://doi.org/10.1016/j.cmet.2017.04.004 Martinez-Vicente M, Cuervo A (2007) Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet 6:352–361. https://doi.org/10.1016/S1474-4422(07)70076-5 Colella B, Faienza F, Bartolomeo S (2019) EMT regulation by autophagy: a new perspective in glioblastoma biology. Cancers (Basel) 11:312. https://doi.org/10.3390/cancers11030312 Galluzzi L, Pietrocola F, Bravo-San Pedro J et al (2015) Autophagy in malignant transformation and cancer progression. EMBO J 34:856–880. https://doi.org/10.15252/embj.201490784 Amaravadi R, Lippincott-Schwartz J, Yin X et al (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17:654–666. https://doi.org/10.1158/1078-0432.CCR-10-2634 López-Otín C, Blasco M, Partridge L et al (2013) The hallmarks of aging. Cell 153:1194–1217. https://doi.org/10.1016/j.cell.2013.05.039 Boya P, Reggiori F, Codogno P (2013) Emerging regulation and functions of autophagy. Nat Cell Biol 15:713–720. https://doi.org/10.1038/ncb2788 Laplante M, Sabatini D (2009) mTOR signaling at a glance. J Cell Sci 122:3589–3594. https://doi.org/10.1242/jcs.051011 Wong P, Puente C, Ganley I et al (2013) The ULK1 complex: sensing nutrient signals for autophagy activation. Autophagy 9:124–137. https://doi.org/10.4161/auto.23323 Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177–183. https://doi.org/10.1007/s10014-011-0029-1 Frattini V, Trifonov V, Chan J et al (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45:1141–1149. https://doi.org/10.1038/ng.2734 Cordani M, Butera G, Pacchiana R et al (2017) Molecular interplay between mutant p53 proteins and autophagy in cancer cells. Biochim Biophys Acta Rev Cancer 1867:19–28. https://doi.org/10.1016/j.bbcan.2016.11.003 Jutten B, Rouschop K (2014) EGFR signaling and autophagy dependence of growth, survival, and therapy resistance. Cell Cycle 13:42–51. https://doi.org/10.4161/cc.27518 Mathew R, Karp C, Beaudoin B et al (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell 137:1062–1075. https://doi.org/10.1016/j.cell.2009.03.048 Chen J, Zhang P, Chen W et al (2015) ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells. Autophagy 11:239–252. https://doi.org/10.1080/15548627.2015.1009767 Padmakrishnan CJ, Easwer HV, Vijayakurup V et al (2019) High LC3/Beclin expression correlates with poor survival in glioma: a definitive role for autophagy as evidenced by in vitro autophagic flux. Pathol Oncol Res 25:137–148. https://doi.org/10.1007/s12253-017-0310-7 Hou J, Han Z, Jing Y et al (2013) Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells. Cell Death Dis 4:884. https://doi.org/10.1038/cddis.2013.338 García-Prat L, Martínez-Vicente M, Periguero E et al (2016) Autophagy maintains stemness by preventing senescence. Nature 529:37–42. https://doi.org/10.1038/nature16187 Martinez-Outschoorn U, Prisco M, Ertel A et al (2011) Ketones and lactate increase cancer cell “stemness”, driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via metabolo-genomics. Cell Cycle 10:1271–1286. https://doi.org/10.4161/cc.10.8.15330 Ricci-Vitiani L, Pallini R, Biffoni M et al (2010) Tumor vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824–828. https://doi.org/10.1038/nature09557 Galavotti S, Bartesaghi S, Faccenda D et al (2013) The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 32:699–712. https://doi.org/10.1038/onc.2012.111 Katayama M, Kawaguchi T, Berger M et al (2007) DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14:548–558. https://doi.org/10.1038/sj.cdd.4402030 Natsumeda M, Aoki H, Miyahara H et al (2011) Induction of autophagy in temozolomide treated malignant gliomas. Neuropathology 31:486–493. https://doi.org/10.1111/j.1440-1789.2010.01197.x Filippi-Chiela E, Bueno e Silva M, Thomé M, et al (2015) Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage. Autophagy 11:1099–1113. https://doi.org/10.1080/15548627.2015.1009795 Lefranc F, Kiss R (2006) Autophagy, the Trojan horse to combat glioblastomas. Neurosurg Focus 20:E7. https://doi.org/10.3171/foc.2006.20.4.4 Lum J, Bauer D, Kong M et al (2005) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120:237–248. https://doi.org/10.1016/j.cell.2004.11.046 Chen J, Li Y, Yu T et al (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522–526. https://doi.org/10.1038/nature11287 Auffinger B, Tobias A, Han Y et al (2014) Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ 21:1119–1131. https://doi.org/10.1038/cdd.2014.31 Zhu H, Wang D, Liu Y et al (2013) Role of the hypoxia-inducible factor-1 alpha induced autophagy in the conversion of the non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells. Cancer Cell Int 13:119. https://doi.org/10.1186/1475-2867-13-119 Koukourakis MI, Mitrakas AG, Giatromanolakis A (2016) Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. Br J Cancer 114:485–496. https://doi.org/10.1038/bjc.2016.19 Ogier-Denis E, Codogno P (2003) Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta 1603:113–128. https://doi.org/10.1016/s0304-419x(03)00004-0 Kanzawa T, Germano IM, Komata T et al (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448–457. https://doi.org/10.1038/sj.cdd.4401359 Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740. https://doi.org/10.1200/JCO.2008.19.8721 Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745. https://doi.org/10.1200/JCO.2008.16.3055 Nagane M, Nishikawa R, Narita Y et al (2012) Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 42:887–895. https://doi.org/10.1093/jjco/hys121 Vredenburgh J, Desjardins A, Herndon J II et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729. https://doi.org/10.1200/JCO.2007.12.2440 Bao S, Wu Q, Sathornsumetee S et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843–7848. https://doi.org/10.1158/0008-5472.CAN-06-1010 Jahangiri A, Flanigan P, Aghi MK (2016) Antiangiogenic therapy for glioblastoma. In: Brem S, Abdullah KG (eds) Glioblastoma, vol 10. Elsevier, Philadelphia, pp 143–146 Hombach-Klonisch S, Mehrpour M, Shojaei S et al (2018) Glioblastoma and chemoresistance to alkylating agents: involvement of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther 184:13–41. https://doi.org/10.1016/j.pharmthera.2017.10.017 Hu Y-L, DeLay M, Jahangiri A et al (2012) Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 72:1773–1783. https://doi.org/10.1158/0008-5472.CAN-11-3831 Clark AJ, Lamborn KR, Butowski NA et al (2012) Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery 70:361–370. https://doi.org/10.1227/NEU.0b013e3182314f9d Pascolo S (2016) Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies. Eur J Pharmacol 771:139–144. https://doi.org/10.1016/j.ejphar.2015.12.017 Lee SW, Kim H-K, Lee N-H et al (2015) The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett 360:195–204. https://doi.org/10.1016/j.canlet.2015.02.012 Rosenfeld MR, Ye X, Supko JG et al (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359–1368. https://doi.org/10.4161/auto.28984 Braicu C, Zanoaga O, Zimta A-A et al (2020) Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: controlling the uncontrolled expansion of tumor cells. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2020.05.015 Lin S-R, Change C-H, Hsu C-F et al (2019) Natural compounds as potential adjuvants to cancer therapy: preclinical evidence. Br J Pharmacol 177:1409–1423. https://doi.org/10.1111/bph.14816 Hasima N, Ozpolat B (2014) Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis 5:e1509. https://doi.org/10.1038/cddis.2014.467 Zhou J, Li G, Zheng Y et al (2015) A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission. Autophagy 8:1259–1279. https://doi.org/10.1080/15548627.2015.1056970 Taylor MA, Khathayer F, Ray SK (2019) Quercetin and sodium butyrate synergistically increase apoptosis in rat C6 and human T98G glioblastoma cells through inhibition of autophagy. Neurochem Res 44:1715–1725. https://doi.org/10.1007/s11064-019-02802-8 Chakrabarti M, Ray SK (2015) Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. Apoptosis 21:312–328. https://doi.org/10.1007/s10495-015-1198-x Chakrabarti M, Klionsky DJ, Ray SK (2016) miR-30e blocks autophagy and acts synergistically with proanthocyanidin for inhibition of AVEN and BIRC6 to increase apoptosis in glioblastoma stem cells and glioblastoma SNB19 cells. PLoS ONE 11:e0158537. https://doi.org/10.1371/journal.pone.0158537 Racoma IO, Meisen WH, Wang Q-E et al (2013) Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. PLoS ONE 8:e72882. https://doi.org/10.1371/journal.pone.0072882 Pazhouhi M, Sariri R, Rabzia A et al (2016) Thymoquinone synergistically potentiates temozolomide cytotoxicity through the inhibition of autophagy in U87MG cell line. Iran J Basic Med Sci 19:890–898. https://doi.org/10.22038/IJBMS.2016.7472 Lin C-J, Lee C-C, Shih Y-L et al (2012) Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med 52:377–391. https://doi.org/10.1016/j.freeradbiomed.2011.10.487 Boridy S, Le PU, Petrecca K et al (2014) Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells. Cell Death Dis 5:e1216. https://doi.org/10.1038/cddis.2014.182 Yuan G, Yan S-F, Xue H et al (2014) Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivo. J Biol Chem 289:10607–10619. https://doi.org/10.1074/jbc.M113.528760 Liu A-J, Wang S-H, Chen K-C et al (2013) Evodiamine, a plant alkaloid, induces calcium/JNK-mediated autophagy and calcium-mitochondria-mediated apoptosis in human glioblastoma cells. Chemico-biol Interact 205:20–28. https://doi.org/10.1016/j.cbi.2013.06.004 Wang J, Qi Q, Feng Z et al (2016) Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway. Oncotarget 7:66944–66958. https://doi.org/10.18632/oncotarget.11396 Singletary K, Milner J (2008) Diet, autophagy, and cancer: a review. Cancer Epidemiol Biomark Prev 17:1596–1610. https://doi.org/10.1158/1055-9965.EPI-07-2917 Shen S, Zhang Y, Zhang R et al (2014) Ursolic acid induces autophagy in U87MG cells via ROS-dependent endoplasmic reticulum stress. Chemico-biol Interact 218:28–41. https://doi.org/10.1016/j.cbi.2014.04.017 Jing Z, Han W, Sui X et al (2015) Interaction of autophagy with microRNAs and their potential therapeutic implications in human cancers. Cancer Lett 356:332–338. https://doi.org/10.1016/j.canlet.2014.09.039 Ma B, Yuan Z, Zhang L et al (2017) Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy. Biochim Biophys Acta 1864:1393–1404. https://doi.org/10.1016/j.bbamcr.2017.05.008 Yang AI, Maus MV, O’Rourke DM (2016) General principles of immunotherapy for glioblastoma. In: Brem S, Abdullah KG (eds) Glioblastoma, vol 19. Elsevier, Philadelphia, pp 237–246 Kaminska B, Ciechomska IA, Cyranowski S (2020) Chapter 3—autophagy in brain tumor immune evasion and responses to immunotherapy. In: Chouaib S (ed) Autophagy in immune response: impact on cancer immunotherapy. Academic, London, pp 29–52 Li T-F, Xu Y-H, Li K et al (2019) Doxorubicin–polyglycerol–nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy. Acta Biomater 86:381–394. https://doi.org/10.1016/j.actbio.2019.01.020 Zhao L, Xu Y-H, Akasaka T et al (2014) Polyglycerol-coated nanodiamond as a macrophage-evading platform for selective drug delivery in cancer cells. Biomaterials 35:5393–5406. https://doi.org/10.1016/j.biomaterials.2014.03.041 Liu J-R, Yu C-W, Hung P-Y et al (2019) High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhances antitumor immunity in glioblastoma. Biochem Pharmacol 163:458–471. https://doi.org/10.1016/j.bcp.2019.03.023 Hottinger AF, Abdullah KG, Stupp R (2016) Current standards of care in glioblastoma therapy. In: Brem S, Abdullah KG (eds) Glioblastoma, vol 6. Elsevier, Philadelphia, pp 73–80 Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543. https://doi.org/10.1001/jama.2015.16669 Silginer M, Weller M, Stupp R et al (2017) Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis 8:e2753. https://doi.org/10.1038/cddis.2017.171 Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619. https://doi.org/10.1038/nrg1879 Wu Y-T, Tan H-L, Shui G et al (2010) Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 285:10850–10861. https://doi.org/10.1074/jbc.M109.080796 Zhang X, Li W, Wang C et al (2014) Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells. Mol Cell Biochem 385:265–275. https://doi.org/10.1007/s11010-013-1835-z Wang J, Qi Q, Zhou Q et al (2018) Inhibition of glioma growth by flavokawain B is mediated through endoplasmic reticulum stress induced autophagy. Autophagy 14:2007–2022. https://doi.org/10.1080/15548627.2018.1501133 Jin X, Liu Y, Liu X et al (2014) Role of autophagy in high linear energy transfer radiation-induced cytotoxicity to tumor cells. Cancer Sci 105:770–778. https://doi.org/10.1111/cas.12422 Kim J, Lee J-W, Kim S-I et al (2011) Thrombin-induced migration and matrix metalloproteinase-9 expression are regulated by MAPK and PI3K pathways in C6 glioma cells. Korean J Physiol Pharmacol 15:211–216. https://doi.org/10.4196/kjpp.2011.15.4.211 Blommaart EF, Krause U, Schellens JP et al (1997) The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem 243:240–246. https://doi.org/10.1111/j.1432-1033.1997.0240a.x Mahadevan D, Chiorean EG, Harris WB et al (2012) Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer. https://doi.org/10.1016/j.ejca.2012.06.027 Fedrigo CA, Grivicich I, Schunemann DP et al (2011) Radioresistance of human glioma spheroids and expression of HSP70, p53, and EGFR. Radiat Oncol 6:156. https://doi.org/10.1186/1748-717X-6-156 Ryabaya OO, Inshakov AN, Egorova AV et al (2017) Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro. Anticancer Drugs 28:307–315. https://doi.org/10.1097/CAD.0000000000000463 Deng L, Lei Y, Liu R et al (2013) Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis 4:e614. https://doi.org/10.1038/cddis.2013.142 Venugopal C, Hallett R, Vora P et al (2015) Pyrvinium targets CD133 in human glioblastoma brain tumor-initiating cells. Clin Cancer Res 21:5324–5337. https://doi.org/10.1158/1078-0432.CCR-14-3147 Li Y, Yao J, Han C et al (2016) Quercetin, inflammation, and immunity. Nutrients 8:167. https://doi.org/10.3390/nu8030167 Kim H, Moon JY, Ahn KS et al (2013) Quercetin induces mitochondrial mediated apoptosis and protective autophagy in human glioblastoma U373MG cells. Oxid Med Cell Longev. https://doi.org/10.1155/2013/596496 Egan DF, Chun MG, Vamos M et al (2015) Small molecule inhibition of autophagy kinase ULK1 and identification of ULK1 substrates. Mol Cell 59:285–297. https://doi.org/10.1016/j.molcel.2015.05.031 Mauthe M, Orhon I, Rocchi C et al (2018) Chloroquine inhibits autophagy flux by decreasing autophagosome–lysosome fusion. Autophagy 14:1435–1455. https://doi.org/10.1080/15548627.2018.1474314 Cristofori AD, Ferrero S, Bertolini I et al (2015) The vacuolar H+ ATPase is a novel therapeutic target for glioblastoma. Oncotarget 6:17514–17531. https://doi.org/10.18632/oncotarget.4239 Liu L-Q, Wang S-B, Shao Y-F et al (2019) Hydroxychloroquine potentiates the anti-cancer effect of bevacizumab on glioblastoma via the inhibition of autophagy. Biomed Pharmacother 118:109339. https://doi.org/10.1016/j.biopha.2019.109339 Michaelides M, Stover N, Francis P et al (2011) Retinal toxicity associated with hydroxychloroquine and chloroquine. Arch Ophthalmol 129:30–39. https://doi.org/10.1001/archophthalmol.2010.321 Trejo-Solís C, Serrano-Garcia N, Escamilla-Ramírez Á et al (2018) Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma. Int J Mol Sci 19:3773. https://doi.org/10.3390/ijms19123773 Voldborg BR, Damstrup L, Spang-Thomsen M et al (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8:1197–1206. https://doi.org/10.1023/a:1008209720526 Ostrom QT, Liao P, Stetson LC et al (2016) Epidemiology of glioblastoma and trends in glioblastoma survivorship. In: Brem S, Abdullah KG (eds) Glioblastoma, vol 2. Elsevier, Philadelphia, pp 11–19 Abdullah KG, Adamson C, Brem S (2016) The molecular pathogenesis of glioblastoma. In: Brem S, Abdullah KG (eds) Glioblastoma, vol 3. Elsevier, Philadelphia, pp 21–31 Chang C-Y, Kuan Y-H, Ou Y-C et al (2014) Autophagy contributes to gefitinib-induced glioma cell growth inhibition. Exp Cell Res 327:102–112. https://doi.org/10.1016/j.yexcr.2014.05.011 Chang C-Y, Shen C-C, Su H-L et al (2011) Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation. J Neuro-oncol 105:507–522. https://doi.org/10.1007/s11060-011-0632-3 Chang C-Y, Li J-R, Wu C-C et al (2015) Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy. IUBMB Life 67:869–879. https://doi.org/10.1002/iub.1445 Bilir A, Erguven M, Oktem G et al (2008) Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. Int J Oncol 32:829–839. https://doi.org/10.3892/ijo.32.4.829 Erguven M, Yazihan N, Aktas E et al (2010) Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol 36:857–866. https://doi.org/10.3892/ijo_00000563 Blommaart EF, Luiken JJ, Blommaart PJ et al (1995) Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rate hepatocytes. J Biol Chem 270:2320–2326. https://doi.org/10.1074/jbc.270.5.2320 MacKeigan JP, Krueger DA (2015) Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol 17:1550–1559. https://doi.org/10.1093/neuonc/nov152 Zhuang W-Z, Long L-M, Ji W-J et al (2011) Rapamycin induces differentiation of glioma stem/progenitor cells by activating autophagy. Chin J Cancer 30:712–720. https://doi.org/10.5732/cjc.011.10234 Zhuang W, Li B, Long L et al (2011) Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer 129:2720–2731. https://doi.org/10.1002/ijc.25975 Wang M, Lu KV, Zhu S et al (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66:7864–7869. https://doi.org/10.1158/0008-5472.CAN-04-4392 Takeuchi H, Kondo Y, Fujiwara K et al (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65:3336–3346. https://doi.org/10.1158/0008-5472.CAN-04-3640 Yokoyama T, Iwado E, Kondo Y et al (2008) Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther 15:1233–1239. https://doi.org/10.1038/gt.2008.98 Chheda MG, Wen PY, Hochberg FH et al (2015) Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol 121:627–634. https://doi.org/10.1007/s11060-014-1680-2 Mason WP, MacNeil M, Kavan P et al (2012) A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. Investig N Drugs 30:2344–2351. https://doi.org/10.1007/s10637-011-9775-5 Alonso MM, Jiang H, Yokoyama T et al (2008) Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16:487–493. https://doi.org/10.1038/sj.mt.6300400 Goudar RK, Shi Q, Hjelmeland MD et al (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101–112 Maiti P, Scott J, Sengupta D et al (2019) Curcumin and solid lipid curcumin particles induce autophagy, but inhibit mitophagy and the PI3K-Akt/mTOR pathways in cultured glioblastoma cells. Int J Mol Sci 20:399. https://doi.org/10.3390/ijms20020399 Guo S, Long M, Li X et al (2016) Curcumin activates autophagy and attenuates oxidative damage in EA.hy926 cells via the Akt/mTOR pathway. Mol Med Rep 13:2187–1293. https://doi.org/10.3892/mmr.2016.4796 Zhao J, Zhu J, Lv X et al (2017) Curcumin potentiates the potent antitumor activity of ACNU against glioblastoma by suppressing the PI3K/AKT and NF-κB/COX-2 signaling pathways. Oncotargets Ther 10:5471–5482. https://doi.org/10.2147/OTT.S149708 Karmakar S, Banik NL, Patel SJ et al (2006) Curcumin activated both receptor-mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. Neurosci Lett 407:53–58. https://doi.org/10.1016/j.neulet.2006.08.013 Zhou Y-Y, Li Y, Jiang W-Q et al (2015) MAPK/JNK signalling: a potential autophagy regulation pathway. Biosci Rep 35:e00199. https://doi.org/10.1042/BSR20140141 Jarzabek MA, Amberger-Murphy V, Callanan JJ et al (2014) Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. Br J Cancer 111:2275–2286. https://doi.org/10.1038/bjc.2014.529 Fiveash J (January 2008–June 2012). Gossypol in treating patients with progressive or recurrent glioblastoma multiforme. Identifier NCT00540722. https://clinicaltrials.gov/ct2/show/NCT00540722 Voss V, Senft C, Lang V et al (2010) The pan-Bcl-2 inhibitor (−)-Gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8:1002–1016. https://doi.org/10.1158/1541-7786.MCR-09-0562 Yin D, Wakimoto N, Xing H et al (2008) Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 123:1364–1375. https://doi.org/10.1002/ijc.23648 Agarwal S, Maekawa T (2020) Nano delivery of natural substances as prospective autophagy modulators in glioblastoma. Nanomed Nanotechnol Biol Med 19:102270. https://doi.org/10.1016/j.nano.2020.102270 Lu L, Shen X, Tao B et al (2019) The nanoparticle-facilitated autophagy inhibition of cancer stem cells for improved chemotherapeutic effects on glioblastomas. J Mater Chem B 12:2054–2062. https://doi.org/10.1039/C8TB03165G Ulasov I, Fares J, Timashev P et al (2020) Editing cytoprotective autophagy in glioma: an unfulfilled potential for therapy. Trends Mol Biol 26:252–262. https://doi.org/10.1016/j.molmed.2019.11.001 Ishaq M, Ojha R, Sharma AP et al (2020) Autophagy in cancer: recent advances and future directions. Semin Cancer Biol 66:171–181. https://doi.org/10.1016/j.semcancer.2020.03.010 Ishimwe N, Zhang W, Qian J et al (2020) Autophagy regulation as a promising approach for improving cancer immunotherapy. Cancer Lett 475:34–42. https://doi.org/10.1016/j.canlet.2020.01.034 Kelly C, Majewska P, Ioannidis S et al (2017) Estimating progression-free survival in patients with glioblastoma using routinely collected data. J Neurooncol 135:621–627. https://doi.org/10.1007/s11060-017-2619-1 Seglen PO, Gordon PB (1982) 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci USA 79:1889–1892. https://doi.org/10.1073/pnas.79.6.1889 Vlahos CJ, Matter WF, Hui KY et al (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241–5248. https://doi.org/10.1016/S0021-9258(17)37680-9 Oppermann H, Faust H, Yamanishi U et al (2019) Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling. PLoS ONE 14:e0218972. https://doi.org/10.1371/journal.pone.0218972 Yamamoto A, Tagawa Y, Yoshimori T et al (1998) Bafilomycin A1 prevents maturation of autophagy vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 23:33–42. https://doi.org/10.1247/csf.23.33 Hori YS, Hosoda R, Akiyama Y et al (2014) Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. J Neuro-oncol 122:11–20. https://doi.org/10.1007/s11060-014-1686-9 Bursch W (2006) Multiple cell death programs: Charon’s lifts to Hades. FEMS Yeast Res 5:101–110. https://doi.org/10.1016/j.femsyr.2004.07.006 Coyle T, Levante S, Shetler M et al (1994) In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neurooncol 19:25–35. https://doi.org/10.1007/BF01051046 Hendricks BK, Cohen-Gadol AA, Miller JC (2015) Novel delivery methods bypassing the blood–brain and blood–tumor barriers. Neurosurg Focus 38:E10. https://doi.org/10.3171/2015.1.FOCUS14767 Bunevicius A, McDannold NJ, Golby AJ (2020) Focused ultrasound strategies for brain tumor therapy. Oper Neurosurg (Hagerstown) 19:9–18. https://doi.org/10.1093/ons/opz374 Han C, Gu H, Wang J et al (2013) Regulation of l-threonine dehydrogenase in somatic cell reprogramming. Stem Cells 31:953–965. https://doi.org/10.1002/stem.1335 Morsi RZ, Hage-Sleiman R, Koveissy H (2018) Noxa: role in cancer pathogenesis and treatment. Curr Cancer Drug Targets 18:914–928. https://doi.org/10.2174/1568009618666180308105048 Ciuffreda L, Di Sanza C, Incani UC et al (2012) The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med 90:667–679. https://doi.org/10.1007/s00109-011-0844-1 Hammouda MB, Ford AE, Liu Y et al (2020) The JNK signaling pathway in inflammatory skin disorders and cancer. Cells 9:857. https://doi.org/10.3390/cells9040857 D’Arcy MS (2019) Cell death: a review of the major forms of apoptosis, necrosis, and autophagy. Cell Biol Int 43:582–592. https://doi.org/10.1002/cbin.11137 Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495–516. https://doi.org/10.1080/01926230701320337 Pawlowska E, Szczepanska J, Szatkowska M et al (2018) An interplay between senescence, apoptosis and autophagy in glioblastoma multiforme-role in pathogenesis and therapeutic perspective. Int J Mol Sci 18:889. https://doi.org/10.3390/ijms19030889 Capparelli C, Guido C, Whitaker-Menezes D et al (2012) Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle 11:2285–2302. https://doi.org/10.4161/cc.20718 Xiao M-C, Qian H, Huang C-K et al (2021) Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy. Eur J Pharmacol 906:174217. https://doi.org/10.1016/j.ejphar.2021.174217 Ray SK (2020) Modulation of autophagy for neuroprotection and functional recovery in traumatic spinal cord injury. Neural Regen Res 15:1601–1612. https://doi.org/10.4103/1673-5374.276322